Statements (56)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:pharmaceuticals
|
| gptkbp:atccode |
B03 XA02
|
| gptkbp:bioavailability |
100% (subcutaneous)
|
| gptkbp:chemical_formula |
C210 H250 N38 O45 S
|
| gptkbp:clinical_trial |
Phase III
|
| gptkbp:contraindication |
pure red cell aplasia
uncontrolled hypertension hypersensitivity to darbepoetin alfa |
| gptkbp:dosage_form |
injection solution
|
| gptkbp:drug_interactions |
gptkb:ACE_inhibitors
anticoagulants iron supplements |
| gptkbp:effective_date |
2001-03-27
|
| gptkbp:excretion |
urine
|
| gptkbp:formulation |
single-use vials
multi-dose vials |
| https://www.w3.org/2000/01/rdf-schema#label |
Aranesp
|
| gptkbp:indication |
chronic kidney disease
chemotherapy-induced anemia |
| gptkbp:ingredients |
darbepoetin alfa
|
| gptkbp:invention |
patented
|
| gptkbp:is_monitored_by |
blood pressure
hemoglobin levels iron status |
| gptkbp:legal_status |
prescription only
|
| gptkbp:lifespan |
24 hours
|
| gptkbp:manufacturer |
gptkb:Amgen
|
| gptkbp:market_position |
marketed
|
| gptkbp:marketed_countries |
gptkb:Australia
gptkb:Canada gptkb:European_Union gptkb:Japan gptkb:United_States |
| gptkbp:metabolism |
liver
|
| gptkbp:packaging |
pre-filled syringes
cartridge systems |
| gptkbp:patient_education |
injection technique
side effects awareness importance of adherence |
| gptkbp:patient_population |
cancer patients
chronic kidney disease patients |
| gptkbp:research |
safety studies
clinical efficacy studies comparative studies with epoetin alfa |
| gptkbp:route_of_administration |
subcutaneous injection
|
| gptkbp:service_frequency |
once every 1-4 weeks
|
| gptkbp:side_effect |
fatigue
headache nausea hypertension thromboembolic events |
| gptkbp:storage |
refrigerated
|
| gptkbp:used_for |
gptkb:anemia
|
| gptkbp:weight |
38,000 Da
|
| gptkbp:bfsParent |
gptkb:Procrit
|
| gptkbp:bfsLayer |
6
|